Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
Indications Pneumococcal infections
Focus Adverse reactions; Registrational
Acronyms PNEU-LINK
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

13 Jun 2023 Results assessing the safety and tolerability of V114 pneumococcal vaccine in infants, published in the Pediatrics.
25 Aug 2021 According to a Merck & Co media release, full results will be presented at an upcoming scientific congress.
08 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com